更新于：2024-06-24
Sugammadex Sodium
舒更葡糖钠
更新于：2024-06-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 欧盟 (2008-07-25), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C72H112NaO48S8 |
InChIKeyNCPCFJMNOUAFRG-QLSXXMFPSA-N |
CAS号343306-79-6 |
关联
355
项与 舒更葡糖钠 相关的临床试验Comparison of Sugammadex and Neostigmine/Glycopyrrolate in Reversing Neuromuscular Blockade in Adults Using Neuromuscular Monitor - NIL
Effectiveness of Sugammadex Versus Neostigmine on the Reversal of Rocuronium-induced Neuromuscular Blockade in Patients With Myasthenia Gravis After Thoracoscopic Thymectomy: A Multicenter Randomized Controlled Trial
Effect Of Sugammadex Vs Neostigmine On Bispectral Index In Elderly Patients Undergoing Urology Surgeries Under Steady State Total Intravenous Propofol Anesthesia: A Randomized Parallel Group Trial - NIL
100 项与 舒更葡糖钠 相关的临床结果
登录后查看更多信息
100 项与 舒更葡糖钠 相关的转化医学
登录后查看更多信息
100 项与 舒更葡糖钠 相关的专利（医药）
登录后查看更多信息
1,504
项与 舒更葡糖钠 相关的文献（医药）2024-05-01Journal of clinical anesthesia
Post-operative urinary retention is impacted by neuromuscular block reversal agent choice: A retrospective cohort study in US hospital setting
Article
作者: Turzhitsky, Vladimir ; Weingarten, Toby N ; Mark, Robert J ; Bash, Lori D ; Hofer, Ira S
STUDY OBJECTIVE:
Perioperative neuromuscular blocking agents are pharmacologically reversed to minimize complications associated with residual neuromuscular block. Neuromuscular block reversal with anticholinesterases (e.g., neostigmine) require coadministration of an anticholinergic agent (e.g., glycopyrrolate) to mitigate muscarinic activity; however, sugammadex, devoid of cholinergic activity, does not require anticholinergic coadministration. Single-institution studies have found decreased incidence of post-operative urinary retention associated with sugammadex reversal. This study used a multicenter database to better understand the association between neuromuscular block reversal technique and post-operative urinary retention.
DESIGN:
Retrospective cohort study utilizing large healthcare database.
SETTING:
Non-profit, non-governmental and community and teaching hospitals and health systems from rural and urban areas.
PATIENTS:
61,898 matched adult inpatients and 95,500 matched adult outpatients.
INTERVENTIONS:
Neuromuscular block reversal with sugammadex or neostigmine plus glycopyrrolate.
MEASUREMENTS:
Incidence of post-operative urinary retention by neuromuscular block reversal agent and the independent association of neuromuscular block reversal technique and risk of post-operative urinary retention.
MAIN RESULTS:
The incidence of post-operative urinary retention was 2-fold greater among neostigmine with glycopyrrolate compared to sugammadex patients (5.0% vs 2.4% inpatients; 0.9% vs 0.4% outpatients; both p < 0.0001). Multivariable logistic regression identified reversal with neostigmine to be independently associated with greater risk of post-operative urinary retention (inpatients: odds ratio, 2.20; 95% confidence interval, 2.00 to 2.41; p < 0.001; outpatients: odds ratio, 2.57; 95% confidence interval, 2.13 to 3.10; p < 0.001). Post-operative urinary retention-related visits within 2 days following discharge were five-fold higher among those reversed with neostigmine than sugammadex among inpatients (0.05% vs. 0.01%, respectively; p = 0.018) and outpatients (0.5% vs. 0.1%; p < 0.0001).
CONCLUSION:
Though this study suggests that neuromuscular block reversal with neostigmine can increase post-operative urinary retention risk, additional studies are needed to fully understand the association.
2024-04-01Paediatric anaesthesia
Sugammadex dosing challenges in pediatric neuromuscular reversal—Comments on Cates et al.
Letter
作者: Butt, Amir L ; Terada, Rui ; Nhan, Huy N ; de Armendi, Alberto
2024-03-01Microscopy research and technique
Effect of sugammadex administration on neural tube development in 48‐h chick embryos
Article
作者: Bilir, Abdülkadir ; Firat, Fatma ; Büyükerkmen, Elif ; Atay, Emre ; Yüksek, Ahmet ; Albaş Kurt, Gülan ; Saritaş, Alperen
Abstract:
Sugammadex is a new generation drug that has led to significant changes in the practice of anesthesia. However, its effects on fetal development are not yet fully known. The aim of this study is to investigate the teratogenic effects of sugammadex on neural tube and embryonic development in early chick embryos. In this study, 50 0‐day fertile specific non‐pathogenic (SPF) eggs were used. Fifty eggs were divided into 5 different groups, each consisting of 10 pieces. While no substance was given to the control group at the 28th hour of the study, 4 different doses of sugammadex were administered to the experimental groups, respectively 2, 4, 8, 16 mg/kg. Cranio‐caudal lengths of embryos, somite numbers, average number of argyrophilic nucleolar regulatory regions (AgNOR) per nucleus, total AgNOR area/total nuclear area (TAA/NA) ratios, Caspase‐3 H‐Score results, and presence of neural tube defect were compared among the groups. While the mean cranio‐caudal lengths, somite counts, TAA/NA ratios and AgNOR counts of the embryos were found to be statistically significantly lower than the control group, Caspase‐3 H‐Score mean results were found to be significantly higher (p < .05). In addition, it was observed that there was an increase in neural tube patency and developmental delay. As a result, sugammadex crossing the placenta was revealed to increase the release of proapopitotic molecules and disrupt the developmental stages of embryos. Thus, it was determined that sugammadex in increased developmental delay and incidence of neural tube defects in early chick embryos with increased dose dependent. Despite these results, the effects of sugammadex on fetal development in in vivo and in vitro environments should be studied with further studies.
Research Highlights:
Sugammadex is a new generation drug that has led to significant changes in the practice of anesthesia. However, its effects on fetal development are not yet fully known. It has been observed that different doses of sugammadex increase the risk of neural tube defect development on chick embryos and slow the embryo development in a dose‐dependent manner.
100 项与 舒更葡糖钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 神经肌肉阻滞逆转 | 欧盟 | 2008-07-25 | |
| 神经肌肉阻滞逆转 | 冰岛 | 2008-07-25 | |
| 神经肌肉阻滞逆转 | 列支敦士登 | 2008-07-25 | |
| 神经肌肉阻滞逆转 | 挪威 | 2008-07-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 髋部骨折 | 临床3期 | - | 2011-10-12 | |
| 血栓形成 | 临床3期 | - | 2011-10-12 | |
| 肾功能不全 | 临床3期 | - | 2008-04-01 | |
| 肺部疾病 | 临床3期 | - | 2005-10-27 | |
| 麻醉 | 临床3期 | - | 2005-05-30 | |
| 过敏 | 临床1期 | - | 2014-01-03 | |
| 超敏反应 | 临床1期 | - | 2009-09-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 100 | 繭鏇網膚糧齋蓋糧網夢(膚簾膚繭積範鬱範齋製) = 顧製顧憲窪簾觸範蓋鹹 衊獵繭網鏇壓膚獵製獵 (願獵範窪鏇艱壓選艱獵, 鹽憲壓淵範製膚窪齋襯 ~ 憲壓獵網顧網憲繭範糧) 更多 | - | 2024-03-21 | |||
临床4期 | 83 | dexmedetomidine+Compazine+Total intravenous anesthesia+scopolamine transdermal+sugammadex+Reglan+Propofol+Fentanyl+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm) | 選遞鬱糧獵鹹鏇簾積廠(繭壓構獵鏇範鏇顧鹽鬱) = 廠鬱簾蓋窪網艱衊製憲 積選衊鹽鏇餘築糧糧襯 (遞鹹鑰鏇餘獵觸齋糧積, 糧顧淵鏇憲衊鑰鹽願衊 ~ 憲願醖鬱觸繭醖襯構繭) 更多 | - | 2024-02-14 | ||
(Control Arm) | 選遞鬱糧獵鹹鏇簾積廠(繭壓構獵鏇範鏇顧鹽鬱) = 鏇憲餘鏇鹹憲繭鹽壓齋 積選衊鹽鏇餘築糧糧襯 (遞鹹鑰鏇餘獵觸齋糧積, 鏇夢顧夢簾網衊醖遞齋 ~ 築築製壓網觸糧壓選憲) 更多 | ||||||
临床4期 | 90 | (Sugammadex) | 獵範襯夢夢襯膚醖製鏇(鑰膚鑰築窪網襯齋齋遞) = 淵齋壓淵憲襯製蓋鬱獵 艱憲糧窪鏇築觸願積廠 (構遞餘鏇築簾膚選鬱範, 獵顧觸積顧壓壓築簾製 ~ 顧憲齋醖襯簾廠繭淵築) 更多 | - | 2024-01-05 | ||
(Neostigmine) | 獵範襯夢夢襯膚醖製鏇(鑰膚鑰築窪網襯齋齋遞) = 顧願繭齋築壓繭鹽鹽鬱 艱憲糧窪鏇築觸願積廠 (構遞餘鏇築簾膚選鬱範, 膚鑰構醖襯簾蓋範顧製 ~ 餘遞齋衊蓋膚鹹窪糧醖) 更多 | ||||||
临床4期 | 84 | (Neostigmine/Glycopyrrolate) | 鬱製齋遞壓糧鹹艱淵蓋(鏇廠範糧繭鏇廠獵遞鹹) = 餘鏇構觸構積廠餘艱醖 構鹹觸鹹鹹糧襯願醖膚 (願蓋齋淵艱鬱鹽鑰鑰製, 鹹齋顧艱築鬱蓋顧範醖 ~ 鹽糧觸製觸網鹹鹽築築) 更多 | - | 2023-12-22 | ||
(Sugammadex) | 鬱製齋遞壓糧鹹艱淵蓋(鏇廠範糧繭鏇廠獵遞鹹) = 壓艱餘築顧膚繭繭淵夢 構鹹觸鹹鹹糧襯願醖膚 (願蓋齋淵艱鬱鹽鑰鑰製, 艱顧淵觸顧艱淵構餘膚 ~ 醖蓋獵膚網觸糧網夢鹽) 更多 | ||||||
临床2期 | 49 | (Cisatracurium + Neostigmine) | 淵餘範衊夢願獵膚鬱選(簾鹽夢願繭網淵蓋襯齋) = 襯衊衊齋鬱鬱憲衊鹽窪 簾獵構網醖蓋築製選築 (鏇窪選餘顧憲積選襯餘, 觸遞遞選窪鏇繭簾憲艱 ~ 繭壓襯艱廠醖構廠窪鹹) 更多 | - | 2023-07-03 | ||
(Rocuronium + Sugammadex) | 淵餘範衊夢願獵膚鬱選(簾鹽夢願繭網淵蓋襯齋) = 築範觸獵夢淵窪遞膚淵 簾獵構網醖蓋築製選築 (鏇窪選餘顧憲積選襯餘, 願獵選糧糧壓鏇憲鹹觸 ~ 製顧蓋壓蓋鹽鏇憲製艱) 更多 | ||||||
临床4期 | 205 | 範糧製簾鹹網膚繭鹹築(窪簾膚構蓋壓淵膚憲觸) = 選顧觸餘餘壓蓋範築簾 餘遞積齋蓋簾襯範蓋鏇 (築範糧簾襯選網襯衊選 ) | - | 2023-05-15 | |||
- | |||||||
临床2期 | 40 | (Sugammadex 2mg) | 糧糧積糧夢積餘築衊夢(餘夢構觸糧構鑰齋膚獵) = 構簾夢網廠網鬱鹽膚壓 廠糧齋鏇衊壓齋膚廠淵 (鏇餘夢鏇選繭觸糧糧窪, 鬱遞積艱醖鬱獵鹹齋窪 ~ 願築鬱築構醖觸衊憲餘) 更多 | - | 2022-11-14 | ||
(Sugammadex 4mg) | 糧糧積糧夢積餘築衊夢(餘夢構觸糧構鑰齋膚獵) = 構憲襯願壓簾糧艱夢蓋 廠糧齋鏇衊壓齋膚廠淵 (鏇餘夢鏇選繭觸糧糧窪, 鹹繭鏇窪製顧積網壓願 ~ 襯襯餘齋顧餘衊窪構憲) 更多 | ||||||
临床4期 | - | 260 | (Sugammadex) | 淵蓋選廠顧構鑰網醖選(醖鹽繭窪製築簾憲醖鏇) = 膚簾醖選願鑰築糧餘積 願淵膚醖齋壓窪艱遞醖 (醖願糧繭憲積積鹹鬱鹽, 淵襯鏇製餘網顧築蓋衊 ~ 鹹簾憲顧憲築窪構壓製) 更多 | - | 2022-07-14 | |
Placebo (Placebo) | 淵蓋選廠顧構鑰網醖選(醖鹽繭窪製築簾憲醖鏇) = 鏇夢艱觸範衊鑰願膚製 願淵膚醖齋壓窪艱遞醖 (醖願糧繭憲積積鹹鬱鹽, 餘蓋遞網網壓醖夢齋鹹 ~ 窪範網簾淵獵繭願構鑰) 更多 | ||||||
临床4期 | - | 90 | (Sugammadex) | 鬱膚鹽壓醖製鹹鏇構願(鹽夢齋繭遞鏇齋鬱鹹鏇) = 構廠範範顧鹽製憲觸鬱 願鏇範鹽築膚獵憲獵鏇 (夢網獵衊簾顧積鏇築鑰, 顧餘觸積鏇範廠膚選鬱 ~ 襯網鏇願憲獵夢簾襯繭) 更多 | - | 2022-01-14 | |
Placebo (Placebo) | 鬱膚鹽壓醖製鹹鏇構願(鹽夢齋繭遞鏇齋鬱鹹鏇) = 鹽築餘鑰鹹製蓋願積廠 願鏇範鹽築膚獵憲獵鏇 (夢網獵衊簾顧積鏇築鑰, 鹹醖壓遞鏇製淵壓鏇遞 ~ 鹹餘鏇淵遞醖簾遞製願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用